Skip to main content
. Author manuscript; available in PMC: 2014 Dec 23.
Published in final edited form as: Nat Commun. 2014 Jun 23;5:4234. doi: 10.1038/ncomms5234

Figure 2. SUMO1 and CDK6 are required for glioblastoma progression.

Figure 2

(a) Three cell lines were transduced or not with the indicated vectors (top) and subjected to western blotting using the antibodies as indicated (left). (b) The SUMO1-613 and control shRNA expressing LN229 cells were transfected either with YFP-SUMO1 or His-SUMO1 and examined by western blotting using CDK6, his and GFP antibody that also recognized YFP. (c) Total RNA isolated from the cells as described above in (a) was examined by real time PCR and the mRNA levels of SUMO1 and CDK6 were normalized to the control β-actin mRNA levels (points: means; bar: SD; n = 6 from two independent experiments; *** P < 0.001; ** P < 0.01; NS: no significance; student’s t-test). (d) Kaplan-Meier curves show the survival of the mice transplanted intracranially with LN229 cells transduced or not with the indicated shRNA vectors (n = 10 for each group; *** P < 0.001; Log rank test).